Specific bacterial species can stimulate immune cells known as antigen-presenting cells (APCs), which in turn contribute to diverse T cell responses (including those against tumors) but the identities of the specific APC subsets involved remain unclear. Therefore, Dr. Ranit Kedmi is using molecular and genetic approaches to probe these relationships. Ultimately, she aims to uncover insights that will lay the foundation for the future development of bacteria-based and dendritic cell-based cancer immunotherapies that can overcome pro-tumor immunosuppression and instead promote anti-tumor T cell responses.
New York University Medical Center | All Cancers | 2017 | Dan R. Littman, M.D., Ph.D.
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
We are Generation Cure. On June 11, we celebrated the ninth annual global immunotherapy awareness day to support a future immune to cancer.
Cell therapy development lagged in 2020, but is gaining ground again, a new CRI report shows.